NAK, A POTENTIAL THERAPEUTIC TARGET FOR AIDS

Information

  • Research Project
  • 6145200
  • ApplicationId
    6145200
  • Core Project Number
    R43AI045262
  • Full Project Number
    1R43AI045262-01A1
  • Serial Number
    45262
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/1/2000 - 24 years ago
  • Project End Date
    3/31/2001 - 23 years ago
  • Program Officer Name
    PLAEGER, SUSAN F.
  • Budget Start Date
    4/1/2000 - 24 years ago
  • Budget End Date
    3/31/2001 - 23 years ago
  • Fiscal Year
    2000
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    3/1/2000 - 24 years ago

NAK, A POTENTIAL THERAPEUTIC TARGET FOR AIDS

The accessory protein HIV-Nef plays an important role in the regulation of HIV pathogenesis. Recently we and others have shown that Nef is associated with the host protein kinase known as Nef Associated kinase (NAK). Recruitment of NAK by Nef is an important step for HIV production. NAK inhibitors will introduce a novel class of anti-HIV drugs that will target the host protein rather than viral proteins. To identify NAK, we will purify NAK from T Jurkat cells stably expressing Nef and will use the sequence information to obtain the full length DNA. Our preliminary results suggest that NAK is co-purified with Pak1 and Nef interacts with Pak1 in-vitro and in-vivo. We will further characterize the Pak1 and Nef interaction and will establish if NAK is identical to Pak1. We will make recombinant NAK to study the biochemical events leading to NAK activation and will test the effect of NAK mutants on HIV production. This approach may lead us to the discovery of anti-HIV drugs that will maintain efficacy in a virus that exhibits a high frequency of mutations. PROPOSED COMMERCIAL APPLICATIONS: We previously have shown that the association of HIV Nef with the host protein NAK is essential for HIV replication. Our preliminary results indicate that NAK is identical to known kinase Pak1. The development of a NAK specific inhibitor will allow us to identify a novel class of anti-HIV agents. Our research and development will introduce a novel approach in the development of anti viral agents and will expand our understanding of the mechanism of HIV pathogenesis.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    112854
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:112854\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ONYX PHARMACEUTICALS
  • Organization Department
  • Organization DUNS
  • Organization City
    RICHMOND
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94806
  • Organization District
    UNITED STATES